NORTHBROOK, Ill., May 28, 2009 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today that it will provide cancer related data through three abstracts at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Orlando, Fla. from May 29 to June 2, 2009. The abstracts discuss the use of biomarkers in pre-clinical development, cancer recurrence and clinical needs of novel biomarkers.
Abstract ID: e14594 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Ultra-Sensitive detection of biomarkers and applications in pharmaceutical discovery and development. Example application to rat Cardiac troponin I assay via nanoparticle probes."
Verisens(tm) cTnI Cardiotoxicity Assay is an in vitro diagnostic assay for the high-sensitivity detection and quantification of rat cardiac troponin I (cTnI). The assay is intended to be performed as a testing service for research use only.
For additional information, please contact Nanosphere at cardiotoxicity@nanosphere.us
Abstract ID: e16146 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Detection of prostate cancer recurrence using an ultrasensitive nanoparticle-based PSA assay."
Verisens(tm) PSA is an in vitro diagnostic assay for the high-sensitivity detection and quantification of prostate specific antigen (PSA). The assay was developed in collaboration with the International Institute for Nanotechnology at Northwestern University. It is intended to be performed as a testing service for research use only (see research-use notification below).
For additional information, please contact Nanosphere at psa@nanosphere.us
Abstract ID: e22222 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Biomarkers in cancer: Survey of diagnostic needs."
RESEARCH USE NOTIFICATION
Nanosphere, Inc. is required by the U.S. Food and Drug Administration (FDA) to certify in writing that its customers, who purchase or who are supplied with products labeled "For Research Use Only," acknowledge and understand that such products are not for use in diagnostic or therapeutic procedures. Tests performed with in vitro products intended for "Research Use Only" are tests used in a preclinical or nonclinical setting. While research tests may be performed using either clinical or nonclinical materials, research use devices have no intended clinical use and the testing performed is not designed to provide data addressing or demonstrating safety and effectiveness. We advise our customers to monitor the use of these products, to ensure that they are used for research purposes only. Please contact Nanosphere if you have questions.
The following link provides access to these abstracts: http://abstractsearch.asco.org/cgi-bin/ts.pl?index=442064&query=nanosphere&opt=exact
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene(r) System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
The Nanosphere, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4344